AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03405428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radial artery diameter measurement by ultrasonography
Description: Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
Study NCT03405428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ulnar artery doppler ultrasonography
Description: Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
Study NCT01675193 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Disinvestment protocol
Description: Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
Study NCT05090852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hi-VNI
Description: Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
Study NCT01031368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01031368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV
Study NCT01031368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT03332316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride Inj 2 mg/ml
Description: Ropivacaine injection
Study NCT03332316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study NCT01031368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded cord blood progenitor cell infusion
Description: Undergo ex vivo-expanded cord blood progenitor cell infusion
Study NCT01031368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03315416 — intervention group
Intervention type: OTHER
Intervention: Speech Sound Assessment
Description: Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
Study NCT03332316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study NCT02065817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope of cholesterol
Study NCT01447186 — intervention group
Intervention type: BEHAVIORAL
Intervention: Post-Test Questionnaire
Description: Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
Study NCT01447186 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
Study NCT04762810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and glucocorticoids
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
Study NCT04762810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
Study NCT01317264 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no β-glucan
Description: daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
Study NCT01317264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oat β-glucan
Description: daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
Study NCT01317264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: barley β-glucan
Description: daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days
Study NCT01317264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutant-barley β-glucan
Description: daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days
Study NCT04027504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fitabisc
Description: Biscuits containing antioxidants
Study NCT01490385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED Phototherapy
Study NCT04435093 — intervention group
Intervention type: OTHER
Intervention: MFM-Play
Description: Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
Study NCT01633762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem, gentamicin, vancomycin (together)
Description: 4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)
Study NCT01248429 — intervention group
Intervention type: BIOLOGICAL
Intervention: CPK dosage
Description: CPK dosage during a blood sample realized at least one week after the begining of the treatment
Study NCT01248429 — intervention group
Intervention type: OTHER
Intervention: Clinical exam
Description: Examination of the patient for myalgia, cramps, medical history and concomitant medication
Study NCT06249074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: Diet with gluten elimination followed by all participants for 8 weeks
Study NCT06249074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten-free diet
Description: Diet with gluten elimination followed by all participants for 8 weeks
Study NCT06249074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten capsules supplementation
Description: 2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
Study NCT03914586 — intervention group
Intervention type: DEVICE
Intervention: oXiris filter
Description: Continuous Renal Replacement Therapy with oXiris filter
Study NCT02462278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempuRing
Study NCT03898999 — intervention group
Intervention type: OTHER
Intervention: Overall status
Description: An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
Study NCT00249366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam (drug)
Description: Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
Study NCT00249366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
Study NCT00239642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer (iron sucrose injection)
Description: 0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
Study NCT00239642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer (iron sucrose injection)
Description: 1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
Study NCT00239642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer (iron sucrose injection)
Description: 2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
Study NCT02948309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mistletoe extract (Iscador Qu)
Description: 1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
Study NCT02948309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml subcutaneous injection 3 times/week
Study NCT03277456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Intramuscular injection of novel vaccine
Study NCT01313988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols and fish oil
Description: 4 weeks intervention, 3 times daily
Study NCT01313988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: 4 weeks intervention, 3 times daily
Study NCT01313988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks, 3 times daily
Study NCT06249074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules supplementation
Description: Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
Study NCT03573921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrograﬁn
Description: Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
Study NCT03573921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline solution (control treatment)
Description: Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
Study NCT01447186 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
Study NCT01873625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mesenchymal cell transplantation
Description: Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
Study NCT03747497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: contezolid acefosamil
Description: IV and oral contezolid acefosamil given twice a day for 10 to 14 days
Study NCT03747497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid 600 mg
Description: IV and oral linezolid given twice a day for 10 to 14 days
Study NCT00701064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light Exposure
Description: Administered via bright light box
Study NCT00701064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Ion Generator
Description: Administered via Negative Ion Generatore
Study NCT02186548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed surgical technique
Description: * Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa
Study NCT02186548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical technique
Description: * Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa
Study NCT04221165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Opioids will be prescribed as per institutional standards.
Study NCT03339622 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PPP001
Description: 1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
Study NCT03339622 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
Study NCT05124145 — intervention group
Intervention type: OTHER
Intervention: No intervention (surveillance system)
Description: The surveillance network will collect data on all consecutive COVID-19 cases
Study NCT02291068 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychotherapy treatment
Description: 3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
Study NCT02185729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Infusion of Intralipid (soybean-derived fat)
Study NCT02185729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic
Description: Infusion of ClinOleic (olive oil-based)
Study NCT02185729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: Infusion of dextrose (sugar) without fat
Study NCT02185729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline (control)
Description: Infusion of 0.9% normal saline
Study NCT01953419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed disodium
Description: Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
Study NCT01769846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization protocol
Description: Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
Study NCT01021423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
Study NCT01021423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
Study NCT01817218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Study NCT01817218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osakidetza protocol
Description: Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice.
Study NCT01203566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LESS appendectomy
Description: See under arms description
Study NCT01203566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 3-port laparoscopic appendectomy
Description: See under arms description
Study NCT00540228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A - 4 different formulations
Description: Single dose, Intramuscular injection
Study NCT00540228 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, Intramuscular injection
Study NCT01873625 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01916733 — intervention group
Intervention type: DRUG
Intervention: standard insulin protocol post-op (continuous IV insulin)
Description: concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
Study NCT01283724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (Visanne, BAY86-5258)
Description: Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
Study NCT02277418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAVL
Description: Videolaryngoscope
Study NCT00781859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 µg Ocriplasmin
Description: 125µg ocriplasmin intravitreal injection
Study NCT00781859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravitreal injection
Study NCT02277418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy
Study NCT02184520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRANSITION
Study NCT02184520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REVERE
Study NCT01234142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
Study NCT01234142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
Study NCT01234142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
Study NCT01234142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
Study NCT01234142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: 2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
Study NCT01234142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
Study NCT01883596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution
Description: Bexident® (0.12% chlorhexidine solution)
Study NCT01249547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
Study NCT01883596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.